NCI

National Clinical **Trials** Network



For Patients with Newly Diagnosed Multiple Myeloma EAA181 Available Through ECOG-ACRIN Cancer Research Group

Effective Quadruplet Utilization after Treatment Evaluation (EQUATE): A Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma not Intended for Early Autologous Transplantation

	<u>,</u>
Patient Population:	Treatment Plan:
See Protocol Section 3 for Complete Eligibility Details	See Protocol Section 5 for Complete Treatment Details
Step 0 Pre-Registration:	Cycle= 28 days
• Age \geq 18 years; ECOG PS 0-2 (PS 3 allowed if secondary	Step I- Induction (9 cycles):
to pain); able to have a diagnostic bone marrow aspirate	• Arm A:
Must have suspected/confirmed newly diagnosed MM	Daratumumab-hyaluronidase 1800 mg/30,000
(IMWG); no more than I cycle of treatment	units SC days I, 8, 15, 22 cycles I-2; days I and
• Must be ineligible for autologous stem cell transplanta-	 I5 cycles 3-6; day I cycles 7-9 ♦ Lenalidomide 25 mg PO daily days I-21 cycles I-9
tion/willing to delay stem cell transplantation until first relapse or later (stem cell collection is allowed)	 Dexamethasone 40 mg PO days 1, 8, 15, 22 cycles
 Must agree to register to Celegene Revlimid REMS/ 	I-4; 20 mg PO days I, 8, 15, 22 cycles 5-9
comply with requirements	Step 2- Consolidation (9 cycles) and Maintenance
 No known allergies/hypersensitivity/intolerance to corti- 	(until disease progression):
costeroids, monoclonal antibodies/human proteins, or	• Arm B:
their excipients, or known sensitivity to mammalian-	Onsolidation (9 cycles/ study cycles 10-18):
derived products	Bortezomib 1.3 mg/m ² SC (or IV per proto-
Step Registration:	col) days 1, 8, 15 cycles 1-9
Dominant sequences must have been identified	 Daratumumab-hyaluronidase 1800 mg/30,000
 Must have standard risk MM (R-ISS) Stage I/II and measur- able/evaluable disease defined per protocol; adequate lab 	units SC once every 28 days (day 1) cycles 1- 9
values	
 Must have received no more than 1 cycle (28 days or 	 Lenalidomide 15 mg PO daily days 1-21 cy- cles 1-9 (or dose tolerated in cycle 9)
less) of prior chemotherapy and no more than 160 mg of	 Dexamethasone 12 mg PO days 1, 8, 15, 22
prior dexamethasone (or equivalent dose of prednisone)	cycles I-9 (or dose tolerated in cycle 9)
for treatment of symptomatic myeloma; must not have	♦ <u>Maintenance (study cycles 19+):</u>
been exposed to daratumumab for treatment of sympto- matic myeloma; prior RT to symptomatic lesions is al-	 Daratumumab-hyaluronidase 1800 mg/30,000
lowed per protocol (see protocol for SMM treatment)	units SC once every 28 days (day 1)
 HIV, HBV, HCV patients permitted per protocol 	 Lenalidomide 10 mg PO daily days 1-21
 Must be NYHA class 2B or better/meet cardiac criteria 	• Arm C:
per protocol; DVT or PE patients are permitted if they	Consolidation (9 cycles/ study cycles 10-18): same
are on anti-coagulation	as Arm B WITHOUT Bortezomib
 No peripheral neuropathy ≥ Gr 2 (or Gr 1 with pain) 	Maintenance (study cycles 19+): same as Arm B
• Must not have moderate/severe persistent asthma within	Notes:
the past 2 years/uncontrolled asthma of any classification	 See protocol for pre-medication/daratumumab injection information, and dose modifications
Step 2 Randomization:	 Patients should complete a medication diary for lenalido-
 Institution must have received MRD test results; ade- guate lab values 	mide and dexamethasone each cycle; see protocol for
 Must have completed Step 1 without experiencing pro- 	fertility instructions
gression	• Stem cells can be mobilized after 4 cycles of induction

All Sites: Oncology Patient Enrollment Network (OPEN) https://open.ctsu.org/open


Protocol Information

ECOG-ACRIN Operations-Boston: 857-504-2900, http://ecog-acrin.org (Member Login)

Please Enroll Your Eligible Patients!

Study Chair: Shaji Kumar, MD

Co-Chair: Michael A. Thompson, MD, PhD, FASCO



Refer to Section 5.1 for detailed dosing instructions

۲Ì,

3. Institutions will be notified of the results of the Clonality ID and tracking MRD tests. Patients for whom dominant sequences were identified must submit bone marrow specimen for MRD test.